The Good Fight
Precision, Performance, and Partnership for Cancer Research Pioneers.
Precision, Performance, and Partnership for Cancer Research Pioneers.
Significant progress in diagnosing and treating cancer is only possible because of efforts to understand the biological mechanisms underlying the disease. Whether it’s the elucidation of Novel pathways or the intricate dance of cell signaling, basic research fuels translational research and target identification at the heart of cancer therapies.
The tools that enable this research span a wide range of applications from NGS identification or validation of mutants, CRISPR for gain or loss of function screens, gene expression for sequence validation, and antibody libraries for target identification. Twist is continuously innovating new tools to aid the basic research community and expand applications to speed new discovery.
The information uncovered in basic research provides the foundation for the translational and clinical research that follows. What was learned from the foundational studies is leveraged for the discovery and testing of therapeutics.
Twist Bioscience supports the translation of basic research into clinical approaches by enabling clinical trials, therapy innovation and biomarker discovery through partnerships with our experienced biopharma team for antibody discovery and development. Twist also offers NGS products for comprehensive tumor profiling and tumor immunity profiling as well as studies focused on the genome, transcriptome, and epigenome.
The development of immunotherapeutics has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunization approaches currently available on the market. Twist Biopharma, an arm of Twist Bioscience, was built to overcome this bottleneck by leveraging Twist Bioscience’s world-leading oligonucleotide synthesis platform to build high-quality antibody discovery libraries for better therapeutic discovery and development for:
• Target Identification
• Identifying robust biomarkers for new drug development
• The ability to define a target patient population, based on these biomarkers
• Developing a well-tolerated effective drug with limited off-target toxicities
• Developing drugs fast and cost-effectively
It means working diligently to combat obstacles and seek answers. Not stopping until you’ve done all you could do. It’s partnering with the scientific community as they research the beast we call cancer, with the ultimate goal to eradicate it, or at the very least, prolong the lives of those diagnosed.
This is no easy feat. At Twist, we recognize we are only one part of the very large puzzle, but we know that with our exceptional tools for Drug Discovery and therapeutics development we can (help) fight cancer at every step along the way from basic research to the clinic.
Potential oncogenes and their control elements can be further investigated through the expression of specific proteins to gain a window into their impact on cell health. The ability to rapidly design and order multiple genes containing variants at the single nucleotide polymorphism resolution provides an efficient method to gather actionable data at both the basic science and translational research levels.
Through the discovery of new antibody-based therapeutics with Twist Biopharma and leveraging Twist Libraries you can effectively explore the protein sequence space when looking for potential new therapeutic molecules. Using Twist’s best-in-class DNA variant libraries with Twist Biopharma’s robust Antibody discovery and development platform, we are helping partners to bring new biologic drugs to the clinic at unprecedented speed. We use our focused DNA synthesis to construct phage display libraries and through multiple rounds of binding selection, we enrich for high-affinity clones. This streamlined workflow provides the basis for a variety of tailored services and support for your lead antibody discovery and optimization.
Twist Biopharma offers a range of pre-constructed and validated synthetic antibody libraries, as well as proprietary discovery and optimization capabilities to accelerate antibody discovery against a wide range of therapeutic targets. By leveraging Twist’s unique ability to manufacture DNA at scale, researchers can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery for antibody therapeutic development and antibody-based assays.
Over the past years biomarkers have become essential to the drug discovery and development process. At Twist Biopharma we want to help you streamline your antibody development pipelines by providing tools to rapidly develop highly-specific, potentially life-saving biologics. The process starts with high-quality DNA. Twist’s highly scalable, silicon-based DNA-writing platform offers speed and precision, delivering exact genomic sequences to produce optimal proteins.
Cancer detection and profiling requires robust and sensitive tools to ensure the right information is obtained at every stage, from basic research through translational medicine and into the clinic. Twist’s target enrichment kits, targeted methylation solutions, and custom panels enable a more sensitive detection in samples ranging from cfDNA to tissue samples. The unique properties of Twist’s NGS solution can result in better information fast at a lower cost per sample.
CRISPR technology continues to evolve and remains a key application for identifying genes and pathways that affect DNA repair, cellular growth, proliferation, and more. Twist’s Oligo Pools are ideal for encoding custom gRNA libraries powering genomic screens because their high uniformity reduces noise in results. Twist oligos are available up to 300mer, so their extended length provides the capacity for multiple guides or scaffold sequences on a single oligo, and enables emerging applications including prime editing and synthetic lethality screening.
Long oligos also power Massively Parallel Reporter Assays, allowing for the high throughput evaluation of control elements and nucleotide changes identified through cancer association studies that fall outside the coding sequences of associated genes. Alterations at the sites can greatly affect the expression of genes that impact cancer.
